006280 — GC Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩3tn
- KR₩2tn
Annual cashflow statement for GC Biopharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 136,950 | 69,415 | -19,809 | -42,637 | -29,685 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -21,276 | 47,204 | 79,765 | 91,151 | 114,276 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -45,599 | -62,561 | -141,328 | -183,008 | -72,783 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 125,979 | 119,154 | -5,473 | -53,460 | 99,463 |
| Capital Expenditures | -123,539 | -94,690 | -125,992 | -42,391 | -105,278 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -8,539 | -110,569 | -24,252 | -25,503 | -81,512 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -132,077 | -205,259 | -150,243 | -67,894 | -186,790 |
| Financing Cash Flow Items | -42,611 | 146 | 1,308 | -161 | 1,836 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -41,270 | -2,481 | 100,512 | 93,845 | 111,580 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -46,228 | -80,694 | -55,660 | -27,143 | 26,809 |